PTCT News and Press, PTC Therapeutics Inc.

2026-03-03 10:11:53 ET Palo Alto Investors LP reported a buy of 41,303 shares of PTC Therapeutics (NASDAQ:PTCT) in its February 17, 2026, SEC filing, with an estimated transaction value of $3.00 million based on quarterly average pricing. According to a SEC filing dated Febr...

2026-02-23 07:26:20 ET PTC Therapeutics ( PTCT ) is entering a new phase of growth as newer products begin to replace older revenue sources. I believe the recent launch of Sephience, an oral therapy approved for the treatment of phenylketonuria (PKU), a rare genetic disorder that pr...

2026-02-20 13:25:46 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Glo...

2026-02-20 13:24:59 ET PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call February 19, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript

2026-02-19 16:11:06 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript PTC Therapeutics, Inc...

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire – Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin)   uptake sin...

Travere Therapeutics Inc. (TVTX) is expected to report $0.03 for Q4 2025 Teck Resources Ltd (TECK) is expected to report $0.59 for Q4 2025 Heidmar Maritime Holdings Corp. (HMR) is expected to report $0.05 for Q4 2025 Endava plc American Depositary Shares (each representing one Class A...

2026-02-12 17:41:40 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript PTC Therapeutics, Inc...

PTC Therapeutics Provides Regulatory Update on Translarna™ PR Newswire WARREN, N.J. , Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren...

PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 PR Newswire WARREN, N.J. , Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to...